HomeCompareALBAF vs MRK

ALBAF vs MRK: Dividend Comparison 2026

ALBAF yields 1000000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALBAF wins by $4.7683925249533696e+36M in total portfolio value
10 years
ALBAF
ALBAF
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full ALBAF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — ALBAF vs MRK

📍 ALBAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALBAFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALBAF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALBAF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALBAF
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, ALBAF beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALBAF + MRK for your $10,000?

ALBAF: 50%MRK: 50%
100% MRK50/50100% ALBAF
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

ALBAF
No analyst data
Altman Z
1.3
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALBAF buys
0
MRK buys
0
No recent congressional trades found for ALBAF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALBAFMRK
Forward yield1000000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4.7683925249533696e+36M$56.8K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$9,798.13
Total dividends collected$4.7683311610149396e+36M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ALBAF vs MRK ($10,000, DRIP)

YearALBAF PortfolioALBAF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,206$366.19+$100.00MALBAF
2$934,786,450,701$934,679,439,252.34$12,650$502.35+$934786.44MALBAF
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,407$694.19+$8165787108.56MALBAF
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,585$967.82+$66665884190957.63MALBAF
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$19,342$1,363.89+$508662171058048128.00MALBAF
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$22,913$1,947.19+$3.62723524842849e+21MALBAF
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$27,662$2,823.89+$2.417368115915061e+25MALBAF
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$34,159$4,173.35+$1.5056740286145463e+29MALBAF
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$43,337$6,308.80+$8.764771002818475e+32MALBAF
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$56,776$9,798.13+$4.7683925249533696e+36MALBAF

ALBAF vs MRK: Complete Analysis 2026

ALBAFStock

Alba Mineral Resources plc, together with its subsidiaries, engages in the exploration and development of natural resources primarily in the United Kingdom, Ireland, and Greenland. It primarily explores for gold, graphite, ilmenite, base metal, iron ore, zinc, and lead deposits. The company owns 100% interests in the Clogau gold, and the Gwynfynydd Gold Mine projects located in Wales; 100% interests in the Limerick base metals located in Ireland; the Thule Black Sands, the Amitsoq graphite project, and the Melville Bay iron ore project located in Greenland; and holds a 11.675% direct interest in the Horse Hill project located in the Weald Basin in southern England. Alba Mineral Resources plc was incorporated in 2004 and is based in London, the United Kingdom.

Full ALBAF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this ALBAF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALBAF vs SCHDALBAF vs JEPIALBAF vs OALBAF vs KOALBAF vs MAINALBAF vs JNJALBAF vs ABBVALBAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.